Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05257551 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tempus Small Cell Lung Cancer Observational Study (Sculptor)

StatusRecruiting
PhaseNot specified
SponsorTempus AI
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study Identification, Study Statusv33
  2. Re-verified, no change to tracked fieldsv32
  3. Enrollment increased: 50 → 200 participants Eligibility criteria expanded, about 349 words · Secondary endpoints revised (2) · Publications: 22 to 31 · 1 morev31 Show 4 more changesShow less
    • Eligibility criteria expanded, about 349 words
    • Secondary endpoints revised (2)
    • Publications: 22 to 31
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  4. Primary and study completion dates: Mar 2026 to Mar 2029 Site contacts updated at 5 of 11 sitesv30 Show 1 more changeShow less
    • Site contacts updated at 5 of 11 sites
  5. 2 versions Re-verified since Mar 26, 2025, no change to tracked fieldsv28-v29
Show 26 earlier versionsHide 26 earlier versions
  1. Site contacts updated at 7 of 11 sitesv27
  2. Re-verified, no change to tracked fieldsv26
  3. Study sites: 10 to 11v25
  4. Re-verified, no change to tracked fieldsv24
  5. Eligibility criteria expanded, about 71 wordsv23 See this version in full on ClinicalTrials.gov ↗
  6. 2 versions Re-verified since Apr 2, 2024, no change to tracked fieldsv21-v22
  7. Site details revised at 1 of 10 sitesv20
  8. Site details revised at 1 of 10 sitesv19
  9. Study sites: 9 to 10v18
  10. Site contacts updated at 2 of 9 sitesv17
  11. Re-verified, no change to tracked fieldsv16
  12. Study sites: 8 to 9v15
  13. Site details revised at 1 of 8 sitesv14
  14. Study sites: 7 to 8v13
  15. Site details revised at 1 of 7 sitesv12
  16. Study sites: 6 to 7v11
  17. Study sites: 5 to 6v10
  18. Eligibility criteria expanded, about 19 wordsv9 See this version in full on ClinicalTrials.gov ↗
  19. Study sites: 4 to 5v8
  20. Study sites: 3 to 4v7
  21. Study title expanded, about 2 wordsv6 See this version in full on ClinicalTrials.gov ↗
  22. Start date changed from estimate of Jul 2022 to Jul 13, 2022 Collaborators expanded, about 1 wordv5 Show 1 more changeShow less
    • Collaborators expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  23. Study sites: 2 to 3v4
  24. Trial status: Not Yet Recruiting to Recruiting Start date: May 2022 to Jul 2022 · Study sites: 0 to 2v3 Show 2 more changesShow less
    • Start date: May 2022 to Jul 2022
    • Study sites: 0 to 2
  25. Start date: Mar 2022 to May 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker profiling during standard of care therapy in both first and second line treatment.
Trial Details
NCT Number NCT05257551
Lead Sponsor Tempus AI
Collaborators: AstraZeneca
Conditions Small Cell Lung Cancer
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov